Close Icon We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Products:

Pharma Consulting

Close Icon

Hot topics

Thought leadership

Research and development strategy

Close Icon

Events

Conferences 2018

Awards

Upcoming Webinars

Webinar recordings

Close Icon

Global Search Configuration

Search Site Products & Services
Close Icon

Search by Keyword

Focus
Needs

Pharma intelligence for marketing agencies

Gain insight into the pharmaceutical market landscape – we’ll help you communicate complex ideas clearly and develop customer-centric propositions.

Supporting market access strategy

With the pharma and healthcare sector facing increasing challenges, your clients rely more than ever on independent intelligence. As a marketer, you have to engage with multiple audiences across a variety of channels and to communicate complex information simply and persuasively.

We give you the means to identify future innovation and new market opportunities, develop customer-centric propositions, and keep a close eye on competitors. We can also help with branding, multi-channel communication and more.

What we offer

As the trusted partner of the top 50 pharmaceutical companies and 10 contract research organizations, our pharma intelligence will help you build a complete picture of the market and get access to past, current and future trends and analysis.

How it helps

You’ll get cutting-edge insights on the size and shape of markets, competitive threats, actionable customer perceptions and industry innovations.

Our accurate, reliable intelligence will help you:

Access in-depth knowledge from drug discovery to market access
Acquire a comprehensive understanding of the global pharma market
Get in-depth coverage of the entire pharmaceutical value-chain

Our unique strengths

Understand your clients’ world

Gain comprehensive knowledge of the global pharma market with our complete coverage.

Think ahead

Respond to market events, identify opportunities and anticipate changes by tracking updates impacting the pharmaceutical industry.

Deliver tailored solutions

Use our data and insight to create solutions to suit your clients’ needs.

Benefit from a dedicated service

Our services come with dedicated client service and analyst support.

View more
View Less

Relevant products

Thought leadership

Key benefits:

Build brand credibility
Generate Leads
Effective reporting

Awareness

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Effective reporting

Lead generation

Key benefits:

Direct access to your target Pharma audience
Multi or single channel campaigns
Measurable results

View all content

Scrip

New Chugai CEO Lays Course As He Takes Reins

By Ian Haydock 25 May 2018

Chugai's new CEO Tatsuro Kosaka took up his position in March and is charged with taking the major Japanese company through the next stage of development as key products reach the global market and others begin to face biosimilar competition. In this first part of a two-part exclusive interview, he outlines the firm's vision, approach to R&D and how the strategic alliance with Roche is playing out.

Topic Business strategies Research

View article
Scrip

Remember When Provenge's Price Was Bold? Every New Cancer Drug In 2017 Cost $100,000 Or More

By Jessica Merrill 25 May 2018

The price of new oncology brands doubled in the US from 2013 to 2017, bringing the median annual price to more than $160,000 last year, up from $79,000 in 2013, according to a new IQVIA report. Spending on cancer drugs in the US has doubled since 2012, reaching nearly $50bn in 2017.

Topic Cancer

View article
Scrip

Pfizer's Three-Pronged Oncology Strategy Includes Expanding Ibrance, Xtandi, Developing Blockbuster Combos

By Brenda Sandburg 23 May 2018

Xtandi use in early prostate cancer, lorlatinib as second-line treatment for non-small cell lung cancer and dacomitinib for first-line NSCLC have upcoming user fee dates.

Topic Cancer

View article
Scrip

Missing In Action: China’s Best Shot In Ebola Vaccine Race

By Brian Yang 23 May 2018

As the Congo grapples with the latest outbreak of Ebola, China has approved its first domestically developed vaccine in record time, hailing it a national innovation champion. But as the World Health Organization starts vaccinations in Africa, can China make the cut and compete with global players including Merck & Co?

Topic Vaccines

View article
Pink Sheet

DTC And The Art Of Selling An Establishment Pricing Plan To A Populist President

22 May 2018

The most surprising proposal coming out the Rose Garden drug pricing event was a call for disclosure of prices in DTC ads. As a policy idea, it may be a dud – but that doesn’t mean it isn’t a critical element of the plan.

Topic Drug review Drug approval

View article
Pink Sheet

EMA Tackles Tough Job Of Filling UK Void In Working Parties

By Neena Brizmohun 22 May 2018

The European Medicines Agency has started the difficult task of finding replacements for the UK chairs and members of its numerous working parties and groups who are having to vacate their position because of Brexit.

Topic Brexit

View article
Scrip

Pharma Backs UK Parliament Report As 'No Deal Brexit' Fears Grow

18 May 2018

The pharmaceutical sector has given its backing to a report from MPs which warns that a no-deal Brexit will have a hugely damaging effect on the industry in the country, turning it into "a second-tier state for new and innovative medicines."

Topic Brexit Business strategies

View article
Scrip

Immuno Oncology: What To Watch At ASCO 2018

By Emily Hayes 18 May 2018

Cancer immunotherapy is once again set to dominate the upcoming American Society of Clinical Oncology annual meeting, with a continuing showdown for PD-1 inhibitors in lung cancer, a CAR-T battle, and disappointments for new IO classes.

Topic Cancer

View article
Pink Sheet

CAR-T Therapy In Medicare: National Coverage Policy Could Come In 2019

By Cathy Kelly 18 May 2018

Medicare begins analysis process for CAR-T cancer therapies in response to a request from United Healthcare for a national coverage policy.

Topic Cancer Cell and gene therapy

View article
Pink Sheet

EMA Panel Finalises Safety Probe Into Richter's Fibroid Drug Esmya

By Ian Schofield 18 May 2018

Gedeon Richter’s uterine fibroid drug, Esmya (ulipristal acetate), is expected to be the subject of a safety recommendation by the EMA’s pharmacovigilance committee this week.

Topic Drug approval Drug development landscape Drug review

View article
Datamonitor Healthcare

Profitability Assessment of Branded Generic Inhalers

By Ljlal Syed, Mark Lansdell and David Abramson 17 May 2018

This report examines the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic

Topic Deal trends

Single report
Scrip

First Of Its Kind: Beam Seeks To Erase-And-Replace Single Letters In DNA's Alphabet

By Mandy Jackson 16 May 2018

Beam Therapeutics combines new insights from gene-editing pioneers to allow for single-letter editing of DNA and RNA. The company has raised $87m to develop DNA base-editing for therapies that in some diseases could be more efficient than CRISPR gene editing.

View article
Scrip

NewLink CEO Reflects On Golden Age And Rapid Fall Of IDO

By Emily Hayes 16 May 2018

There is now a move back to the principle of doing randomized Phase II studies before jumping into Phase III, says CEO Chuck Link, as Roche's Genentech exits broad IDO/TDO deal.

Topic Cancer

View article
Datamonitor Healthcare

Gene therapy

15 May 2018

Topic Cell and gene therapy

Full video
Scrip

FDA Refuse-To-File Letter For Alkermes Depression Drug Suggests A Lengthy Commercial Delay

By Jessica Merrill 15 May 2018

CEO Richard Pops called FDA's letter for ALKS 5461 "surprising and troubling." Alkermes had been ramping up to launch the depression drug later this year, though some investors had remained skeptical.

Topic FDA Drug approval

View article

Latest headlines

Pink Sheet

25 May 2018

Brazil Approves First Generic Sovalidi

Link
Pink Sheet

25 May 2018

EMA Consults On Two-Step Process For Release And Shipping Of Investigational Products

Link
Pink Sheet

25 May 2018

After 40 Years, Is Vaccine For Group B Strep On Horizon?

Link
Pink Sheet

25 May 2018

The 'Dead Cat' Strikes Back: What Does US FDA Do With A Challenging Panel Outcome?

Link
Pink Sheet

25 May 2018

Pre-ANDA Meetings Proving Tough To Get – Nearly Half Of Requests Denied

Link
Scrip

25 May 2018

BioMarin Gets Second PKU Approval, Anticipates Slow Ramp-Up For Palynziq

Link
Pink Sheet

25 May 2018

Manufacturing Compliance Updates In Brief From US FDA And The EU

Link
Scrip

25 May 2018

After Phase III Amyloidosis Failure Prothena Slashes Workforce In Restructuring

Link
Scrip

25 May 2018

PACIFIC Pays Off Again For AZ With Imfinzi Lung Cancer OS Success

Link
Scrip

25 May 2018

Astellas Culls Positions Ahead Of Big Expiry

Link
Pink Sheet

25 May 2018

UK Biotech Not Impressed By Govt’s Response To MPs’ Brexit Concerns

Link
Scrip

24 May 2018

Sanofi In Pole Position In Oral Type 1 Diabetes With Zynquista Filings

Link
Pink Sheet

24 May 2018

EMA Clarifies Sponsor's Role In Validating Electronic Systems Used In Clinical Trials

Link
Pink Sheet

24 May 2018

Gene Therapy 'Cassettes' Could Speed, Cheapen Manufacturing, Gottlieb Says

Link
Scrip

24 May 2018

New Chugai CEO Lays Course As He Takes Reins

Link

Next steps

Request a live demo

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

How can we help you?

Our team is always happy to hear from you. Please call us at:

US Toll-Free : +1 888 670 8900
US Toll : +1 908 547 2200
UK & Europe : +44 (20) 337 73737
Australia : +61 2 8705 6907
Japan : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Pharma intelligence for marketing agencies

Supporting market access strategy

Our unique strengths

Understand your clients’ world

Think ahead

Deliver tailored solutions

Benefit from a dedicated service

Relevant products

Below are the Product List

Thought leadership

Awareness

Lead generation

Pharma Intelligence latest insights

Latest headlines

Next steps

This is Contactus Section

Request a live demo

How can we help you?

Report store